Bioxcel Therapeutics Stock In The News
| BTAI Stock | USD 2.71 0.26 8.75% |
The tone or emotional content of news articles related to BioXcel Therapeutics can affect its prices. Positive news sentiment can lead to an increase in demand for BioXcel Therapeutics' stock, while negative news sentiment can lead to a decrease in demand. Our overall analysis of BioXcel Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards BioXcel Therapeutics. The specific impact of BioXcel Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of BioXcel Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using BioXcel Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out BioXcel Therapeutics Backtesting and BioXcel Therapeutics Hype Analysis. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.
BioXcel |
BioXcel Therapeutics Today Top News and Investor Outlook
BioXcel Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide BioXcel and other traded companies coverage. We help investors stay connected with BioXcel headlines for the 25th of April to make an informed investment decision based on correlating the impacts of news items on BioXcel Stock performance. Please note that trading solely based on the BioXcel Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.BioXcel Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the BioXcel earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about BioXcel Therapeutics that are available to investors today. That information is available publicly through BioXcel media outlets and privately through word of mouth or via BioXcel internal channels. However, regardless of the origin, that massive amount of BioXcel data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioXcel Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioXcel Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioXcel Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioXcel Therapeutics alpha.
BioXcel Largest EPS Surprises
Earnings surprises can significantly impact BioXcel Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-08-06 | 2019-06-30 | -0.6 | -0.54 | 0.06 | 10 | ||
2019-03-07 | 2018-12-31 | -0.39 | -0.46 | -0.07 | 17 | ||
2019-11-14 | 2019-09-30 | -0.65 | -0.57 | 0.08 | 12 | ||
2019-05-07 | 2019-03-31 | -0.55 | -0.46 | 0.09 | 16 | ||
2018-05-14 | 2018-03-31 | -0.25 | -0.37 | -0.12 | 48 | ||
2022-08-09 | 2022-06-30 | -1.22 | -1.35 | -0.13 | 10 |
BioXcel Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to BioXcel Therapeutics Stock. The global stock market is bearish. About 60% of major world exchanges and indexes are down. See today's market update for more information.
22nd of April 2024
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expan... at finance.yahoo.com
18th of April 2024
Q1 2024 EPS Estimates for BioXcel Therapeutics, Inc. Lifted by HC Wainwright - MarketBeat at news.google.com
12th of April 2024
BioXcel Therapeutics, Inc. Shares Sold by DAVENPORT Co LLC - Defense World at news.google.com
8th of April 2024
Bioxcel Therapeutics exec sells over 400 in stock at investing.com
4th of April 2024
Disposition of 1067 shares by Frank Yocca of BioXcel Therapeutics at 2.635 subject to Rule... at MacroaxisInsider
25th of March 2024
BioXcel Therapeutics secures 25 million in direct offering at investing.com
22nd of March 2024
Analyst Rating Will BioXcel Therapeutics Inc Stock Lead the Market - InvestorsObserver at news.google.com
15th of March 2024
BioXcel Therapeutics Announces European Patent Offices Grant of Patent for Method of Treat... at finance.yahoo.com
29th of February 2024
Premarket Mover BioXcel Therapeutics Inc Down 2.14 percent - InvestorsObserver at news.google.com
7th of February 2024
Biotech Alert Searches spiking for these stocks today - TipRanks.com - TipRanks at news.google.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioXcel Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioXcel Therapeutics' short interest history, or implied volatility extrapolated from BioXcel Therapeutics options trading.
Check out BioXcel Therapeutics Backtesting and BioXcel Therapeutics Hype Analysis. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.Note that the BioXcel Therapeutics information on this page should be used as a complementary analysis to other BioXcel Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for BioXcel Stock analysis
When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stocks Directory Find actively traded stocks across global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is BioXcel Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.15) | Revenue Per Share 0.047 | Quarterly Revenue Growth 0.58 | Return On Assets (0.75) | Return On Equity (17.67) |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.